Considerations for metabolite pharmacokinetic data in bioavailability/ bioequivalence assessments: Overview of the recent trends

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 4, 2009, Pages 155-165

  Srinivas, Nuggehally R ^a,b  

^a Suramus Biopharm   (India)

^b Drug Development   (India)

Author keywords

Bioavailability, assessments; Bioequivalence, assessments; Metabolites, pharmacokinetic data; Parent compounds, bioavailability, bioequivalence

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; 6 METHOXY 2 NAPHTHYLACETIC ACID; APOVINCAMINIC ACID; ATORVASTATIN; CARENONE; CLOPIDOGREL; DEACETYLDILTIAZEM; DESLORATADINE; DESVENLAFAXINE; DILTIAZEM; DIURETIC AGENT; DRUG METABOLITE; ERLOTINIB; LICARBAZEPINE; LORATADINE; LOSARTAN; MECLOFENOXATE; METRONIDAZOLE; MEVINOLIN; N NORDILTIAZEM; NABUMETONE; OSELTAMIVIR; OXCARBAZEPINE; QUINAPRIL; QUINAPRILAT; SPIRONOLACTONE; TRIFLUSAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VINPOCETINE;

BIOEQUIVALENCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESEARCH; HUMAN; REVIEW; SINGLE DRUG DOSE; TREND STUDY;

EID: 66149168383     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296380     Document Type: Review

References (47)

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry (Draft Guidance): In vivo bioequivalence studies based on population and individual bioequivalence approaches, October 1997.
2. Colburn WA, Keefe DL. Bioavailability and bioequivalence: average, population and/or individual. J Clin Pharmacol. 2000;40:559-560.
3. Yacobi A, Masson E, Moros D, Ganes D, Lapointe C, Abolfathi Z, et al. Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin. J Clin Pharmacol. 2000;40:826-835.
4. Schumaker RC, Metzler CM. The phenytoin trial is a case study of individual bioequivalence. Drug Inf J . 1998;32:1063-1072. (Pubitemid 28531395)
5. Zariffa NM, Patterson SD. Population and individual bioequivalence: lessons from real data and simulation studies. J Clin Pharmacol. 2001;41:811-822. (Pubitemid 32692091)
6. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Final guidance: BA and BE studies for orally administered drug products - general considerations, 2000.
7. Srinivas NR. Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? J Clin Pharmacol. 2004;44:115-119.
8. Mehvar R, Jamali F. Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Clin Pharmacokin. 1997;33:122-141.
9. Boni JR, Korth-BradleyJM, Richards LS, Chiang ST,Hicks DR, Benet LZ. Chiral bioequivalence: effect of absorption rate on racemic etodolac. Clin Pharmacokin. 2000;39:459-469. (Pubitemid 32099472)
10. Garcia-Arieta A, Abad-Santos F, Rodriguez-Martinez, MA, Varas-Polo Y, Novalbos J, Laparidis N, et al. An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies. Chirality 2005;17:470-475. (Pubitemid 41395669)
11. Jackson AJ, Robbie G, Marroum P. Metabolites and bioequivalence. Past and present. Clin Pharmacokin. 2004;43:655-672.
12. Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence. PharmRes . 2004;21:1331-1344. (Pubitemid 39149647)
13. The European Agency for the Evaluation of Medicinal Products, Committee for Products, Committee for proprietary medicinal products. Note for guidance on the investigation of bioavailability/bioequivalence. CPMP/EWP/QWP/1401/98, London, 26 July 2001.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and Bioequivalence studies for orally administered drug products-general considerations, July 2002.
15. Quetglas EG, Campanero MA, Sadaba B, Escolar M, Azanza JR. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Arzneimittelforschung. 2008;58:283-287.
16. Zou JJ, Ji HJ, Wu DW, Yao J, Hu Q, Xiao DW, et al. Bioequivalence and pharmacokinetic comparison of a single 200 mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. Clin Ther . 2008;30:1651-1657.
17. Xu FG, Zhang ZJ, Dong HJ, Tian Y, Liu Y, Chen Y. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers. Arzneimittelforschung. 2008;58:117-121.
18. Mignini F, Tomassoni D, Streccioni V, Traini E, Amenta F. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin Exp Hypertens. 2008;30:95-108.
19. Rojanasthien N, Nasangiam N, Kumsorn B, Roongapinun S, Jengjareon A. Pharmacokinetics and bioequivalence study of the two 20-mg quinapril hydrochloride tablet formulations in healthy Thai male volunteers. J Med Assoc Thai. 2008;91:739-746
20. Bahrami G, Mohammadi B, Sisakhtnezhad S. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci . 2008;864:168-172.
21. Lainesse A, Ozlap Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004;54:600-604. (Pubitemid 39278902)
22. Patel BN, Sharma N, Sanyal M, Shrivastav PS. Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylenlafaxine in human plasma and its application to a bioequivalence study. J PharmBiomed Anal. 2008a;47: 603-611
23. Patel BN, Sharma N, Sanyal M, Prasad A, Shrivastav PS. High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. Biomed Chromatogr. 2008;22:1213-1224.
24. Georgita C, Albu F, David, V, Medvedovici A. Nonlinear calibrations on the assay of diltiazem and two of its metabolites from plasma samples by means of liquid chromatography and ESI/MS2 detection: Application to a bioequivalence study. Biomed Chromatogr . 2008;22:289-297.
25. Di Girolamo G, Opezzo JA, Schere D, Gonzalez CD, Moncalvo JJ. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers? Expert Opin Pharmacother. 2007;8:1415-1423.
26. Sora DL, Udrescu S, David V, Medvedovici A. Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. Biomed Chromatogr. 2007;21:1023-1029. (Pubitemid 47490312)
27. Bienert A, Brzeziniski R, Szalek E, Dubai V, Grzeskowiak E, Dyderski S, et al. Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2006;56:723-728.
28. Oliveria CH, Mederios Silva R, Santagada V, Caliendo G, Perissutti E, Prado Galuppo M, et al., Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration. Int J Clin Pharmacol Ther. 2006;44:142-148. (Pubitemid 43338015)
29. Gatchev E, Brater M, de Mey C. Bioequivalence of a novel oral metronidazole formulation. Arzneimittelforschung. 2006;56:612-616. (Pubitemid 44358654)
30. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46:282-290. (Pubitemid 43260315)
31. Brewster M, Smith JR, Dutkowski R, Robson R. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomized, open-label study. Vaccine 2006;24:44-46.
32. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R, et al. Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard. Biomed Chromatogr. 2006;20:924-936. (Pubitemid 44430552)
33. Mendoza L, Hajduch M, Plausinaitu R, Platilova V, Emritte N, Svoboda M. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers. Pharmazie. 2006;61:805-806 (Pubitemid 44450376)
34. Vlase L, Bodiu B, Leucuta SE. Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. Arzneimittelforschung. 2005;55:664-668. (Pubitemid 41756049)
35. Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS. Studies on the bioequivalence of different strengths of tablets containing clarithromycin. Arzneimittelforschung. 2004;54:588-593. (Pubitemid 39278900)
36. Srinivas NR. Changing need for bioanalysis during drug development. Biomed Chromatogr. 2008;22:235-243.
37. Srinivas NR. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr. 2006;20:383-414. (Pubitemid 43772018)
38. Srinivas NR. Dodging matrix effects in liquid chromatography tandem mass spectrometric assays - Compilation of key learnings and perspectives. Biomed Chromatogr. 2008; DOI:10.1002/bmc.1152.
39. Chambers E, Wagrowski-Diehl D, Lu Z, Mazzeo J. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B. 2007;852:22-34. (Pubitemid 46830084)
40. Liang HR, Foltz RL Meng M, Bennett P. Ionization enhancement in atmospheric pressure chemical ionization and suppression in electrospray ionization between target drugs and stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid Comm Mass Spectrom. 2003;17:2815-2821. (Pubitemid 38029325)
41. Jemal M, Ouyang Z, Chen B, Teitz D. Quantiation of the acid and lactone forms of atorvastatin and its biotransformation products in humans serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Comm Mass Spectr. 1999;13:1003-1015. (Pubitemid 29257202)
42. Srinivas NR. Applicability of nonlinear calibration regression for the determination of parent and metabolite(s) in bioequivalence assessments. Biomed Chromatogr. 2008;22:1315-1317.
43. Medvedovici A, Sora DL, Ionesscu S, Hillberand M, David V. Characterization of a new norfloxacin metabolite monitored during a bioequivalence study by means of mass spectrometry and quantum computation. Biomed Chromatogr. 2008;22:1100-1107.
44. Solans A, Izquierdo I, Donado E, Antonijoan R, Peña J, Nadal T, et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steadystate levels: A randomized, open-label, two-way, crossover, phase I study. Clin Ther. 2008;30:1639-1650.
45. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006;46:S192-S201. (Pubitemid 44656904)
46. Wang C, Quan LH, Guo Y, Liu CY, Liao YH. Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. Int J Pharm. 2007;337:155-160. (Pubitemid 46766618)
47. Uemura N, Onishi T, Mitaniyama A, Kaneko T, Ninomiya K, Nakamura K. et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005;25:199-208. (Pubitemid 40460646)